KRAS-话题@MedSci

#KRAS#

77篇内容 | 4150人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1368983, encodeId=6353136898375, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, objectType=article, longId=47689, objectId=936f4e689f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=936f4e689f6, replyNumber=0, likeNumber=0, createdTime=2015-03-05, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=936f4e689f6, moduleTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=936f4e689f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368982, encodeId=75551368982f2, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Mol Cancer Ther：siRNA成功能沉默KRAS致癌基因, objectType=article, longId=43156, objectId=f83d43156b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f83d43156b3, replyNumber=0, likeNumber=67, createdTime=2014-11-28, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f83d43156b3, moduleTitle=Mol Cancer Ther：siRNA成功能沉默KRAS致癌基因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f83d43156b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368981, encodeId=8a1b136898140, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=CSCO 2014：KRAS野生型转移性结直肠癌靶向药物的一线之争, objectType=article, longId=40459, objectId=36774045945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36774045945, replyNumber=0, likeNumber=82, createdTime=2014-09-20, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36774045945, moduleTitle=CSCO 2014：KRAS野生型转移性结直肠癌靶向药物的一线之争, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36774045945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368980, encodeId=206f13689801e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, objectType=article, longId=34270, objectId=a77a342e036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a77a342e036, replyNumber=0, likeNumber=66, createdTime=2014-05-07, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a77a342e036, moduleTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a77a342e036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368979, encodeId=098d13689e98b, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）, objectType=article, longId=33909, objectId=cae8339099f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cae8339099f, replyNumber=0, likeNumber=80, createdTime=2014-04-30, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cae8339099f, moduleTitle=Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cae8339099f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368978, encodeId=908a13689e89e, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Nat Commun：Kras/Lkb1/Lox可能是肺腺癌向肺鳞癌转化的关键分子机制, objectType=article, longId=30843, objectId=6e0630843d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e0630843d0, replyNumber=0, likeNumber=82, createdTime=2014-02-21, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e0630843d0, moduleTitle=Nat Commun：Kras/Lkb1/Lox可能是肺腺癌向肺鳞癌转化的关键分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e0630843d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368977, encodeId=96ef13689e7d8, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=JCO：不推荐以KRAS状态作为NSCLC患者接受辅助化疗的标准, objectType=article, longId=17951, objectId=ce181e951cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce181e951cf, replyNumber=0, likeNumber=50, createdTime=2013-05-08, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce181e951cf, moduleTitle=JCO：不推荐以KRAS状态作为NSCLC患者接受辅助化疗的标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce181e951cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368976, encodeId=9c1713689e6cd, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=LANCET ONCOL :Selumetinib与多西他赛联合治疗KRAS基因突变晚期NSCLC疗效佳, objectType=article, longId=12811, objectId=3d99128118f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d99128118f, replyNumber=0, likeNumber=64, createdTime=2012-12-12, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d99128118f, moduleTitle=LANCET ONCOL :Selumetinib与多西他赛联合治疗KRAS基因突变晚期NSCLC疗效佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d99128118f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368975, encodeId=1b2313689e5dd, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Cancer：基因KRAS突变与晚期肺腺癌患者更短存活相关联, objectType=article, longId=8408, objectId=3968840823, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3968840823, replyNumber=0, likeNumber=78, createdTime=2012-08-02, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3968840823, moduleTitle=Cancer：基因KRAS突变与晚期肺腺癌患者更短存活相关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3968840823)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368974, encodeId=647313689e4ad, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=Br J Cancer: HRMA识别KRAS突变优于直接测序, objectType=article, longId=8095, objectId=85ef80953c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ef80953c, replyNumber=0, likeNumber=88, createdTime=2012-07-25, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ef80953c, moduleTitle=Br J Cancer: HRMA识别KRAS突变优于直接测序, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85ef80953c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368973, encodeId=63ee13689e344, content=<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>, objectTitle=美批准确定癌症患者KRAS突变的新检测法, objectType=article, longId=7726, objectId=8163e726a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8163e726a0, replyNumber=0, likeNumber=75, createdTime=2012-07-11, rootId=0, userName=yinhl1978, userId=8217292, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8163e726a0, moduleTitle=美批准确定癌症患者KRAS突变的新检测法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8163e726a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

KRAS

2020-05-29

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究

2015-03-05

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Mol Cancer Ther：siRNA成功能沉默KRAS致癌基因

2014-11-28

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

CSCO 2014：KRAS野生型转移性结直肠癌靶向药物的一线之争

2014-09-20

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果

2014-05-07

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Lancet Oncol：帕尼单抗对KRAS野生型转移性结直肠癌非劣于西妥昔单抗（ASPECCT研究）

2014-04-30

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Nat Commun：Kras/Lkb1/Lox可能是肺腺癌向肺鳞癌转化的关键分子机制

2014-02-21

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

JCO：不推荐以KRAS状态作为NSCLC患者接受辅助化疗的标准

2013-05-08

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

LANCET ONCOL :Selumetinib与多西他赛联合治疗KRAS基因突变晚期NSCLC疗效佳

2012-12-12

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Cancer：基因KRAS突变与晚期肺腺癌患者更短存活相关联

2012-08-02

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

Br J Cancer: HRMA识别KRAS突变优于直接测序

2012-07-25

yinhl1978 (审核中...)

前往app查看评论内容

#KRAS#

美批准确定癌症患者KRAS突变的新检测法

2012-07-11

科室
- - 订阅+
  - 更多科室
工具
服务